| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/10/2002 | CN1357367A Medicine powder for treating epilepsy radically and its prepn |
| 07/10/2002 | CN1357359A Drug addiction stopping machine medicine and its prepn |
| 07/10/2002 | CN1357353A Drug addiction stopping medicine |
| 07/10/2002 | CN1357333A Application of hydrochloric acid in preparing medicine for tumor |
| 07/10/2002 | CN1357320A Taurine chewing gum and its making process |
| 07/10/2002 | CN1087294C Novel compounds |
| 07/10/2002 | CN1087290C 4-aminotetrahydrobenzisoxazole or-isothiazole compounds |
| 07/09/2002 | US6417334 Antagonists to chaperonin 10 |
| 07/09/2002 | US6417329 Purified polypeptide |
| 07/09/2002 | US6417327 Peptide capable of regulating physiological function of FGF-5 and pharmaceutical composition containing the peptide |
| 07/09/2002 | US6417237 Macromolecular drug complexes and compositions containing the same |
| 07/09/2002 | US6417229 Enzyme inhibitors |
| 07/09/2002 | US6417227 Methods of delivery of cetyl myristoleate |
| 07/09/2002 | US6417222 [2-substituted-5-[3-thienyl)-benzyl]-2- ([2-isopropoxy-5-fluoro]-phenyoxy)-ethyl]-amine derivatives, method for the production and use thereof as medicaments |
| 07/09/2002 | US6417221 Tropane analogs and methods for inhibition of monoamine transport |
| 07/09/2002 | US6417218 Substituted imidazoles, their preparation and use |
| 07/09/2002 | US6417212 Modulators of peroxisome proliferator activated receptors |
| 07/09/2002 | US6417209 Heterocyclic ketone and thioester compounds and uses |
| 07/09/2002 | US6417198 Benzothiazole ketone derivatives for nervous system disorders such as cognition activators |
| 07/09/2002 | US6417192 Pyrimidinone compounds and pharmaceutical compositions containing them |
| 07/09/2002 | US6417189 Drugs with pyrazole ketone derivatives |
| 07/09/2002 | US6417188 Arylalkanoylpyridazines |
| 07/09/2002 | US6417185 Heterocyclic enzyme inhibitors |
| 07/09/2002 | US6417183 1,4-diazacycloheptane derivatives |
| 07/09/2002 | US6417178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits |
| 07/09/2002 | US6417177 Chloroquine derivatives for the treatment of Parkinson's disease |
| 07/09/2002 | US6417173 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
| 07/09/2002 | US6417162 Female impotence treated with heterocyclic compound containing nitro groups |
| 07/09/2002 | US6417010 Methods and apparatus for synthesizing labeled combinatorial chemistry libraries |
| 07/09/2002 | US6416991 Genetic engineered protein |
| 07/09/2002 | US6416976 TrpS |
| 07/09/2002 | US6416975 Human glycine transporter type 2 |
| 07/09/2002 | US6416795 Herbal extract composition for stress prevention and treatment |
| 07/09/2002 | CA2221592C Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction |
| 07/09/2002 | CA2217455C New substituted derivatives, of biphenyl or phenylpiridine, their preparation process and the pharmaceutical compositions that contain them |
| 07/09/2002 | CA2041224C Azatetracycle compounds |
| 07/04/2002 | WO2002052273A1 Screening method based on siah-numb interaction |
| 07/04/2002 | WO2002052267A1 A method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| 07/04/2002 | WO2002052019A2 22437, a human sulfatase and uses therefor |
| 07/04/2002 | WO2002052004A1 Gene involved in apoptosis regulation |
| 07/04/2002 | WO2002051983A2 Novel compounds and compositions as cathepsin inhibitors |
| 07/04/2002 | WO2002051981A2 Defects in periaxin associated with myelinopathies |
| 07/04/2002 | WO2002051868A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 07/04/2002 | WO2002051844A1 Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
| 07/04/2002 | WO2002051840A1 Method for producing the anticholinergic agent tiotropium bromide |
| 07/04/2002 | WO2002051838A1 Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists |
| 07/04/2002 | WO2002051837A2 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 07/04/2002 | WO2002051835A1 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| 07/04/2002 | WO2002051833A1 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders |
| 07/04/2002 | WO2002051832A2 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands |
| 07/04/2002 | WO2002051821A1 Therapeutic compounds |
| 07/04/2002 | WO2002051814A1 Benzoylpyridazines |
| 07/04/2002 | WO2002051808A2 Muscarinic antagonists |
| 07/04/2002 | WO2002051807A1 Compounds |
| 07/04/2002 | WO2002051806A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| 07/04/2002 | WO2002051805A1 Indole derivatives as ligands of thyroid receptors |
| 07/04/2002 | WO2002051442A1 Concomitant drugs |
| 07/04/2002 | WO2002051440A1 Combination drugs |
| 07/04/2002 | WO2002051438A2 Use of repulsive guidance molecule (rgm) and its modulators |
| 07/04/2002 | WO2002051435A2 New therapeutic uses of smr1 peptides |
| 07/04/2002 | WO2002051434A2 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 07/04/2002 | WO2002051433A2 Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament |
| 07/04/2002 | WO2002051429A2 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages |
| 07/04/2002 | WO2002051428A1 Sympathetic-activating perfume composition |
| 07/04/2002 | WO2002051418A1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
| 07/04/2002 | WO2002051416A1 Drugs for improving ability of daily life behaviors in alzheimer's disease |
| 07/04/2002 | WO2002051415A2 Use of sequestrants for treating prion diseases |
| 07/04/2002 | WO2002051402A1 Controlled release formulation of divalproex sodium |
| 07/04/2002 | WO2002051401A2 Controlled release formulations of divalproex sodium |
| 07/04/2002 | WO2002051398A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof |
| 07/04/2002 | WO2002051389A2 Aerogel powder comprising therapeutic agents |
| 07/04/2002 | WO2002051232A2 Novel benzazepines and related heterocyclic derivatives |
| 07/04/2002 | WO2002036556A3 Acylaminoalkyl-substituted benzenesulfonamide derivatives |
| 07/04/2002 | WO2002033100A3 Regulation of human adenylate cyclase, type iv |
| 07/04/2002 | WO2002033042A3 Recombinant antibody fragments as autoantibody antagonists |
| 07/04/2002 | WO2002032373A3 Estrogen receptor modulators |
| 07/04/2002 | WO2002028347A3 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 07/04/2002 | WO2002025279A3 Use of amyloid precursor protein for treating brain amyloidosis |
| 07/04/2002 | WO2002022627A3 Ligands for metabotropic glutamate receptors |
| 07/04/2002 | WO2002020609A3 Interleukin-11 for the treatment of stroke and neuropathies |
| 07/04/2002 | WO2002012346A8 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 07/04/2002 | WO2002005848A3 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 07/04/2002 | WO2001092213A3 Excitatory amino acid receptor modulators |
| 07/04/2002 | WO2001091682A8 Composition and applicator for topical substance delivery |
| 07/04/2002 | WO2001090148A8 Neurotransmitter transporters |
| 07/04/2002 | WO2001078768A3 Targeted vaccine delivery systems |
| 07/04/2002 | WO2001078711A3 Pde-v inhibitors for treatment of parkinson's disease |
| 07/04/2002 | WO2001077175A3 G protein-coupled receptors |
| 07/04/2002 | WO2001077169A3 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 07/04/2002 | WO2001068855A3 Gtp-binding protein gamma-12 subunit |
| 07/04/2002 | WO2001068080A3 Neutral antagonists and use thereof in treating drug abuse |
| 07/04/2002 | WO2001062257A3 Bupropion metabolites and methods of their synthesis and use |
| 07/04/2002 | WO2001046176A3 Non peptide tachykinin receptor antagonists |
| 07/04/2002 | WO2001045692A9 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| 07/04/2002 | WO2001032183A3 Pharmaceutical compositions comprising oxcarbazepine |
| 07/04/2002 | WO2000075116A3 Tricyclic analgesics |
| 07/04/2002 | WO2000069900A9 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 07/04/2002 | US20020087012 By cyanide exchange reaction of the corresponding halo- or perfluoroalkylsulfonyl substituted citalopram derivative, film distillation |
| 07/04/2002 | US20020087001 Antipsychotic activity but no cataleptic effects, not induce extrapyramidal side effects; 1-(4-(4-((4-fluorophenyl) (4-methylthien-2-yl)methylene)piperidin-1-yl)-1-oxobutyl)-piperidine salt for example |
| 07/04/2002 | US20020086996 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates |